400,000 Shares in Neuronetics, Inc. $STIM Bought by Ghisallo Capital Management LLC

Key Points

• Ghisallo Capital Management LLC has purchased 400,000 shares of Neuronetics, Inc., valuing their stake at approximately $1.47 million, representing 0.61% of the company.
• Neuronetics reported a loss of $0.15 EPS for Q2, which was below analysts' expectations, despite revenue of $38.11 million exceeding estimates.
• The stock currently has a consensus rating of "Buy" with a price target set at $7.00 by Canaccord Genuity, down from a previous target of $8.00.

Ghisallo Capital Management LLC bought a new stake in Neuronetics, Inc. (NASDAQ:STIM - Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 400,000 shares of the company's stock, valued at approximately $1,472,000. Ghisallo Capital Management LLC owned 0.61% of Neuronetics as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. Larson Financial Group LLC acquired a new position in Neuronetics in the first quarter valued at about $25,000. KPP Advisory Services LLC acquired a new position in Neuronetics in the first quarter valued at about $37,000. National Bank of Canada FI boosted its position in Neuronetics by 19,491.5% in the first quarter. National Bank of Canada FI now owns 11,559 shares of the company's stock valued at $42,000 after buying an additional 11,500 shares in the last quarter. FORA Capital LLC acquired a new position in Neuronetics in the first quarter valued at about $42,000. Finally, Presidio Capital Management LLC acquired a new position in Neuronetics in the first quarter valued at about $44,000. Institutional investors own 53.59% of the company's stock.

Neuronetics Trading Up 1.2%

Shares of STIM traded up $0.04 on Thursday, reaching $3.31. 1,886,577 shares of the company's stock were exchanged, compared to its average volume of 1,237,276. The company has a current ratio of 2.02, a quick ratio of 1.84 and a debt-to-equity ratio of 1.76. The stock has a market capitalization of $218.86 million, a P/E ratio of -2.93 and a beta of 1.28. The business has a 50 day moving average price of $3.75 and a two-hundred day moving average price of $4.01. Neuronetics, Inc. has a 12 month low of $0.52 and a 12 month high of $5.92.

Neuronetics (NASDAQ:STIM - Get Free Report) last issued its earnings results on Tuesday, August 5th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.07). Neuronetics had a negative net margin of 43.47% and a negative return on equity of 156.36%. The firm had revenue of $38.11 million during the quarter, compared to the consensus estimate of $36.80 million. Neuronetics has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. Research analysts anticipate that Neuronetics, Inc. will post -1.13 earnings per share for the current year.

Wall Street Analyst Weigh In

Separately, Canaccord Genuity Group reduced their price target on shares of Neuronetics from $8.00 to $7.00 and set a "buy" rating on the stock in a research report on Wednesday, August 6th. One investment analyst has rated the stock with a Buy rating, According to MarketBeat, Neuronetics has an average rating of "Buy" and a consensus target price of $7.00.

Neuronetics Profile

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.